Document is current
Any future updates will be listed below
-
Authors
Grady, Connor B. https://orcid.org/0000-0001-8407-846X
Bhattacharjee, Bornali https://orcid.org/0000-0002-0801-1543
Silva, Julio https://orcid.org/0000-0001-8212-7440
Jaycox, Jillian
Lee, Lik Wee
Silva Monteiro, Valter https://orcid.org/0000-0003-1785-6713
Sawano, Mitsuaki https://orcid.org/0000-0003-2789-1758
Massey, Daisy
Caraballo, César
Gehlhausen, Jeff R.
Tabachnikova, Alexandra
Mao, Tianyang https://orcid.org/0000-0001-9251-8592
Lucas, Carolina https://orcid.org/0000-0003-4590-2756
Peña-Hernandez, Mario A.
Xu, Lan
Tzeng, Tiffany J.
Takahashi, Takehiro
Herrin, Jeph
Güthe, Diana Berrent
Akrami, Athena
Assaf, Gina
Davis, Hannah
Harris, Karen
McCorkell, Lisa
Schulz, Wade L.
Griffin, Daniel https://orcid.org/0000-0001-5853-6906
Wei, Hannah
Ring, Aaron M.
Guan, Leying https://orcid.org/0000-0003-0609-1073
Dela Cruz, Charles
Krumholz, Harlan M.
Iwasaki, Akiko https://orcid.org/0000-0002-7824-9856
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 20 January 2024
Accepted: 28 March 2025
First Online: 9 May 2025
Competing interests
: In the past three years, H.M.K. received expenses and/or personal fees from United Health, Element Science, Eyedentifeye and F-Prime; he is a co-founder of Refactor Health and HugoHealth; and is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid Services and through Yale University from the Food and Drug Administration, Johnson & Johnson, Google and Pfizer. A.I. co-founded and consults for RIGImmune, Xanadu Bio and PanV and is a member of the Board of Directors of Roche Holding and Genentech. No other authors declare competing interests.
